Genetic markers predict response to antioxidants and zinc in patients with AMD

TORONTO — Genotype-directed nutritional therapy could double the reduction in rate of progression to advanced age-related macular degeneration compared with therapy with the AREDS formulation, a speaker said here.In a genetic analysis of 995 AREDS patients grouped by AREDS category, Carl C. Awh, MD, and colleagues concluded that genetic risk markers CFH and ARMS2 can predict response to antioxidants and zinc in patients with moderate AMD.“For example, CFH binds zinc,” Awh told colleagues at the American Society of Retina Specialists meeting. “This neutralizes its ability to inhibit C3.”

Full Story →